The Sinopharm and Sinovac vaccines have been approved by Chinese health authorities for conditional marketing. Following their authorization for adults, they have continued to carry out expanded clinical trials, and they have been proven safe for the 3 to 17 age group after careful evaluation and expert reviews. The results show that these vaccines have a strong capability to induce the production of antibodies.